THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS NO. 596/2014 AS IT FORMS.
Avacta appoints new Chief Executive Officer Christina Coughlin, MD PhD Clinical proof-of-concept demonstrated for Avacta s lead programme AVA6000 and proof-of-mechanism for the.
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024 Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage
In a small phase 2 trial, subcutaneous exenatide led to a significant reduction in intracranial pressure and number of monthly headaches in patients with IIH.